1048P Cardiovascular toxicities in cancer patients treated with immune checkpoint inhibitors: Evidence from a Belgian real-world multicenter study von Delombaerde, D.L., Oeste, C.L., Verbiest, A.T.L., Tack, L., Croes, L., Bassez, I., Hens, D.F.E., Franssen, C., Debruyne, P.R., Prenen, H., De Sutter, J., Vulsteke, C.

Volltext

1056P Real-world usage and adverse events (AE) of immune checkpoint inhibitors (ICI): A large-scale, automated, GDPR-compliant analysis of hospital records von Verbiest, A.T.L., Debruyne, P.R., Bassez, I., Delombaerde, D.L., Tack, L., Oeste, C.L., Deckx, L., Croes, L., Hens, D.F.E., Geldhof, V., Prenen, H., Vulsteke, C.

Volltext

247P Real-world evidence of immune checkpoint inhibitor treatment in lung cancer patients from a Belgian multicenter study von Geldhof, V., Oeste, C.L., Verbiest, A.T.L., Delombaerde, D.L., Bassez, I., Hens, D.F.E., Derijcke, S., Vulsteke, C.

Volltext

114P Real-world insights on pan-cancer immune checkpoint inhibitor treatment: Initial findings of a Belgian multicenter study von Verbiest, A.T.L., Delombaerde, D.L., Verhaert, M., Tack, L., Oeste, C.L., Cool, L., Croes, L., Bassez, I., Hens, D.F.E., Franssen, C., Aspeslagh, S., Geldhof, V., Debruyne, P.R., Vulsteke, C.

Volltext